Marksans Pharma Share Price Slumps 14% to Four-Month Low After Weak Q1 Results

Market Performance

Marksans Pharma share price plunged 14.28% on August 12, touching a four-month low of ₹180 per share.

The sharp fall came after the company reported disappointing June quarter (Q1 FY26) results, triggering heavy selling pressure.

The stock has been on a downtrend:

• Down 26% in the past month
• Down 36% so far in 2025
• In contrast, it had delivered +84% returns in 2024 and +176% in 2023

Main News

The pharmaceutical company posted weak earnings for the quarter ended June 2025, impacted by lower sales in key geographies and higher operational costs.

Key financial highlights:

• Net Profit: ₹58.2 crore, down 34.7% YoY
• Total Revenue: ₹620 crore, up 5% YoY, but down 12.5% QoQ

Profitability was hit by:

• Higher employee costs due to new hires at an acquired facility
• A one-time Expected Credit Loss (ECL) provision of ₹10.48 crore for the Emerging Market Division

Company Details

Revenue Performance by Region

• UK & Europe: ₹203.8 crore (-19% YoY, -25.7% QoQ)
• Australia & New Zealand: ₹57 crore (-13.1% YoY, -25% QoQ)
• US & North America: ₹327 crore (+30.6% YoY), boosted by launches in gastrointestinal, pain management, and digestive health segments

The growth in the US business helped offset declines in other markets, but overall revenue momentum remained weak.

Summary

The steep fall in the Marksans Pharma share price reflects investor concerns over weak Q1 numbers and ongoing challenges in certain markets.

Despite strong growth in the US segment, revenue drops in Europe, Australia, and New Zealand weighed heavily on performance.

The company remains optimistic about recovery in the coming quarters, but near-term sentiment remains cautious amid global pricing pressures.